A RETROSPECTIVE STUDY ON POST- OPERATIVE THYROID REMNANT ABLATION IN DIFFERENTIATED THYROID CANCER BY I-131: COMPARISON BETWEEN SUCCESS OF LOW AND HIGH DOSE.
Abstract
The first and most important step in the management of differentiated thyroid carcinoma is to reduce the chance of recurrence and death. I-131 ablation represents the most specific anti-neoplastic measures in differentiated thyroid cancer. Ablation of thyroid tissue remnant with radioactive iodine (I-131) reduces the risk of recurrence and increases the survival rate.
We studied retrospectively thyroid remnant ablation with low and high dose of I-131 and compare their success. Total 54 patients of low-dose group treated with 20-50 mCi of I-131 and 159 patients of high dose group treated with 100 mCi of I-131 were included in this study. After first dose both group shows variable success (33% versus 62% low dose versus high dose respectively) but nearly similar success in both groups after second dose (81% versus 77% respectively).
From our study it can be concluded that the use of two low doses at 6-12 months interval could be an acceptable and effective method to ablate post-operative thyroid remnant, particularly the young subjects or in the situation of limited hospital bed.
Besides minimizing the whole body and gonadal irradiation exposure, the advantages are more convenience and reduce the expenses with a dose that can be given as an outpatient. In spite of all advantages the disadvantages are that about half of the patients will require more than one dose to ablate and delay in achieving complete ablation.
Downloads
Metrics
References
Hurley JR, Becker DV. The use of radio-iodine in the management of thyroid cancer. In: Freeman LM, Weissman HS (eds). Nuclear Medicine Annual. New york: Raven press, 1983:329-84.
Hurley JR, Becker DV. Treatment of thyroid cancer with Radio-iodine. In: Sandler MP, Patton JA, et al. (eds). Diagnostic Nuclear Medicine 3rd Edition Vo. 2, Baltimore: Williams & Wilkins, 1996: 959-89.
Pacini F, Lari R, Mazzeo S, Grasso L, Tuddei D, Pinchera A. Diagnostic value of a single serum thyroglobin on and off thyroid suppressive therapy in the followup of patients with differentiated thyroid cancer. Clin Endocrinol 1985;23:405-11.
Pochin EE. Radio-iodine therapy of thyroid cancer. Semin Nucl Med 1971;1: 503-15.
Black BM, Kirk TA, Woolner LB. Multicentricity of papillary adenocarcinoma of the thyroid, influence of treatment. J Clin Endocrinol Metab 1960;22:130-5.
Mazzaferri EL and Young RL. Papillary thyroid cancer. A 10 year follow-up. Am J Med 1981;70:511.
Leeper RD. The effect of therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 1973;36,1143-52.
Henk JM, Kirman S and Owen GM. Whole body scanning of I-131 therapy in the management of thyroid carcinoma. Br J Radio 1972;45:369-76.
Coakley Aj, Page CJ and Croft D. Scanning dose and detection of thyroid metastases (letter). J Nucl Med 1980;21: 803.
Beierwaltes WH. The treatment of thyroid carcinoma with radioactive iodine. Semi Nucl Med 1978;8:79-94.
Varma VM, Beierwaltes WH, Noafl MM, Nishiyama RH and Kopp JE. Treatment of thyroid cancer; death rate after surgery and after surgery followed by sodium 1-131. JAMA 1970;214:1437-42.
Mazzaferri EL and Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994:97:418-28.
Degroot LJ, Reilly M. Comparison of 30- 50 mCi doses for I-131 for thyroid ablation. Ann Intern med 1982;12:51-3.
Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Malleltte S. An analysis of “ablation of thyroid remnants” with I-131 in S11 patients from 1947-1984: Experience at University of Michigan. J Nucl Med 1984;25: 1287-93.
Sammuel AM, Rajashekharrao’ B. Radio-iodine therapy for well differentiated thyroid cancer: A quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994;35:1944-50.
Cruetzig H. high or low dose radio-iodine ablation of thyroid remnants. EurJ Nucl Med 1987;12:500-2.
Johansen K, Woodhouse NJY, Odugbsan O. Comparison of 1073-3700 MBg I-131 in post operative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991;32: 252-4.
Maxon HR, thomas SR, Hertzberg VS, Boehinger A. Relation between effective radiation dose and outcome of radio-iodine therapy for thyroid cancer. N Eng J Med 1983;309:937-41.
McCowen Kd, Adler RA, Ghaed N, Verdon T, Hofeldt FD. Low dose radioiodine thyroid ablation in post surgical patients with thyroid cancer. Am J Med 1976;61:52-8.
Ramacciotti C, Pretorius HT, Line BR, Goldman JM and Robbins J. Ablation of non-malignant thyroid remnants with low doses of radio-active iodine: concise communication. J Nucl Med 1982;23:483-9.
Leung SF, Law MWM and Ho SKW. Efficacy of low dose I-131 ablation of post-operative thyroid remnants: a study of 69 cases. BrJ Radiol 1992;65:905-9
Bal CS, Padhy AK, Jana S, Basu AK. Comparison of low and high dose I-131 ablation of remnant in differentiated thyroid cancer patients. In: Rao Rs Deo MG Sanghvi LD (eds). Proceedings of the XVI international cancer congress; 1994, Oct 30-Nov 5; New Delhi, 1994:1059-63.
Chandrasekhar Bal, Ajit K Padhy, Gauri S. Pant, AK _ Basu. Prospective Randomized Clinical Trial to evaluate the Optimal Dose of I-131 for Remanant Ablation in Patients with Differentiated Thyroid Carcinoma. Cancer 1996;77: 2574-80.
Ryff-De-Leche A, StaubJ-J, Kohler-Faden R, Muller-Brand J, Heitz PU. Thyroglobin production by malignant thyroid tumours: an immunocytochemical and radio-immunoassay study. Cancer 1986;57:1145-53.
Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (First of two parts). N Engl J Med 1979;301:239-49, Control of thyroglobulin synthesis and secretion (second of two parts). 307-14.
Refetoff S and Lever EG. The value of serum thyroglobulin measurement in linical practice. JAMA 1983;250:2352-7.
Ashcraft MW and Van Herle AJ. The comparative value of serum thyroglobin measurement and iodine-131 total body scan in the follow up study of patients with treated differentiated thyroid cancer. Am J Med 1981;71:806-14.
Girelli ME, Busnardo B, Amerio R, Casara D, Betterle C, Piccolo M. Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg level after hormone withdrawal and total body scan: results in 291 patient with thyroid cancer. EurJ Nucl Med 1986;11:333-5.
Ozata M, Suzuki S, Miyamoto T, Liu RT, Feerro-Renoy F. Degroot LJ. Serum thyroglobulin the follow up of patients with treated differentiated thyroid cancer. J clin Endocrinol metab 1994;79:98-105.
Lubin E, Mechilis-frish S, Zatz S, etal. Serum thyroglobulin and I-131 whole body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994;35: 4:257-62.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)
